Tango Therapeutics, Inc. Investing Cash Flow
Tango Therapeutics, Inc. (TNGX) reported Investing Cash Flow of -$436.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$445.97M, a 2758.08% decline year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $9.63M, a 68.51% decline year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$135.72M, a 360.69% decline year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $47.48M, a 45.77% increase year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$40.87M, a 147.45% decline from fiscal 2024.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $86.13M, a 107.90% increase from fiscal 2023.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $41.43M, a 56.92% increase from fiscal 2022.
- Tango Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $26.40M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 4 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 7 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$445.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$436.34M 10-Q · filed 2026-08-11 | -$572.05M derived: sum of 3 quarters · filed 2026-08-11 | -$524.58M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $9.63M 10-Q · filed 2026-05-13 | -$126.08M derived: sum of 2 quarters · filed 2026-05-13 | -$78.61M derived: sum of 3 quarters · filed 2026-05-13 | -$61.83M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$135.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$88.24M derived: sum of 2 quarters · filed 2026-03-05 | -$71.46M derived: sum of 3 quarters · filed 2026-08-11 | -$40.87M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $47.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $64.25M derived: sum of 2 quarters · filed 2026-08-11 | $94.85M 10-Q · filed 2025-11-04 | $146.91M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $16.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $47.38M 10-Q · filed 2026-08-11 | $99.44M derived: sum of 3 quarters · filed 2026-08-11 | $132.00M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $30.60M 10-Q · filed 2026-05-13 | $82.66M derived: sum of 2 quarters · filed 2026-05-13 | $115.23M derived: sum of 3 quarters · filed 2026-05-13 | $127.93M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $52.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $84.63M derived: sum of 2 quarters · filed 2026-03-05 | $97.33M derived: sum of 3 quarters · filed 2026-03-05 | $86.13M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $32.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $45.27M derived: sum of 2 quarters · filed 2025-11-04 | $34.07M 10-Q · filed 2025-11-04 | $67.92M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-06-30 | $12.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.50M 10-Q · filed 2025-08-05 | $35.35M derived: sum of 3 quarters · filed 2026-03-05 | -$21.32M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-03-31 | -$11.20M 10-Q · filed 2025-05-12 | $22.65M derived: sum of 2 quarters · filed 2026-03-05 | -$34.02M derived: sum of 3 quarters · filed 2026-03-05 | -$1.33M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2023-12-31 | $33.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$22.81M derived: sum of 2 quarters · filed 2026-03-05 | $9.88M derived: sum of 3 quarters · filed 2026-03-05 | $41.43M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | -$56.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$23.98M derived: sum of 2 quarters · filed 2024-11-06 | $7.57M 10-Q · filed 2024-11-06 | -$5.03M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $32.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $64.24M 10-Q · filed 2024-08-07 | $51.63M derived: sum of 3 quarters · filed 2025-02-27 | $66.86M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $31.55M 10-Q · filed 2024-05-08 | $18.95M derived: sum of 2 quarters · filed 2025-02-27 | $34.17M derived: sum of 3 quarters · filed 2025-02-27 | $69.67M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | -$12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.62M derived: sum of 2 quarters · filed 2025-02-27 | $38.12M derived: sum of 3 quarters · filed 2025-02-27 | $26.40M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $15.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $50.72M derived: sum of 2 quarters · filed 2023-11-08 | $39.00M 10-Q · filed 2023-11-08 | -$6.20M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $35.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $23.78M 10-Q · filed 2023-08-07 | -$21.43M derived: sum of 3 quarters · filed 2023-08-07 | -$173.65M derived: sum of 4 quarters · filed 2023-08-07 | |||
| 2022-03-31 | -$11.72M 10-Q · filed 2023-05-09 | -$56.92M derived: sum of 2 quarters · filed 2023-05-09 | -$209.14M derived: sum of 3 quarters · filed 2023-05-09 | -$215.76M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$45.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$197.42M derived: sum of 2 quarters · filed 2023-03-27 | -$204.05M derived: sum of 3 quarters · filed 2023-03-27 | -$183.43M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | -$152.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$158.84M derived: sum of 2 quarters · filed 2022-11-10 | -$138.23M 10-Q · filed 2022-11-10 | -$197.44M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $13.99M 10-Q · filed 2022-08-10 | $32.51K 10-Q · filed 2021-08-09 | -$45.22M derived: sum of 3 quarters · filed 2022-08-10 | |||
| 2021-03-31 | $20.61M 10-Q · filed 2022-05-11 | -$38.60M derived: sum of 2 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | -$59.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$166.75M 10-K · filed 2021-03-31 | -$145.47M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | -$166.75M 10-Q · filed 2020-11-13 | -$86.26M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |